Schizophrenia news from FiercePharma
NewsWyeth to slash another 1,200 jobs
And the ax is falling again. Wyeth notified employees last Friday than another 1,200 jobs will be slashed from the payroll. That's on top of the Read more...
Zyprexa shot gets panel's OK
A few hours of extreme drowsiness is not a bad trade-off for schizophrenia patients who have problems sticking to their medication. So said an FDA advisory committee yesterday in backing approval of Read more...
New Zyprexa set for FDA review
First-line or second-line? That, apparently, is the big question for tomorrow's FDA advisory panel meeting. The committee on psychiatric products will consider Eli Lilly's new injectable form of the Read more...
SPOTLIGHT: AZ wants to sell Seroquel for bipolar use
AstraZeneca has asked the FDA to expand the use of its schizophrenia drug Seroquel to treatment of bipolar disorder. Read more...
Bristol's Abilify gets nod for adolescents
Better late than never, Bristol-Myers Squibb might say. In a move that's sure to incite debate, the FDA says it will allow BMS to market its schizophrenia med Abilify for use in adolescents. The Read more...
AZ hit with Crestor patent challenge
It's a one-two punch for AstraZeneca today. A Canadian drug maker is challenging AZ's patent on the cholesterol drug Crestor, one of its top sellers at $2 billion--and a linchpin of its profits over Read more...
Lilly strengthens Zyprexa warnings
Eli Lilly is owning up to Zyprexa's ills in new warnings added to the medicine's Read more...
SPOTLIGHT: Deal or no deal for Lilly?
Remember the expert witness who leaked damaging documents about Zyprexa, Eli Read more...
Risperdal OK'd for children
It might sound like a candidate for the So What? award, but the FDA's approval of the "atypical" antipsychotic Risperdal for use in children and adolescents is a landmark decision. The Read more...
| Press ReleasesPRESS RELEASE: Forest Laboratories High Dose of Schizophrenia Drug Doesn't Meet Goal Forest Laboratories High Dose of Schizophrenia Drug Doesn't Meet Goal NEW YORK and BUDAPEST, Hungary, Oct. 15 -- Forest Laboratories and Gedeon Richter today announced preliminary top-line results Read more... PRESS RELEASE: Potential new drug found for schizophrenia Potential new drug found for schizophrenia PITTSBURGH, Sept. 24 U.S. researchers have developed a drug that promises to treat the cognitive deficits associated with schizophrenia. The scientists Read more... PRESS RELEASE: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds New approach for treatment of schizophrenia An Read more... PRESS RELEASE: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds New approach for treatment of schizophrenia An Read more... PRESS RELEASE: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds New approach for treatment of schizophrenia An Read more... |
Get more Schizophrenia coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight